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Abstract: Kallikrein 13 (KLK13) was first identified as an enzyme that is downregulated in a subset
of breast tumors. This serine protease has since been implicated in a number of pathological
processes including ovarian, lung and gastric cancers. Here we report the design, synthesis and
deconvolution of libraries of internally quenched fluorogenic peptide substrates to determine the
specificity of substrate binding subsites of KLK13 in prime and non-prime regions (according
to the Schechter and Berger convention). The substrate with the consensus sequential motive
ABZ-Val-Arg-Phe-Arg-ANB-NH2 demonstrated selectivity towards KLK13 and was successfully
converted into an activity-based probe by the incorporation of a chloromethylketone warhead and
biotin bait. The compounds described may serve as suitable tools to detect KLK13 activity in diverse
biological samples, as exemplified by overexpression experiments and targeted labeling of KLK13 in
cell lysates and saliva. In addition, we describe the development of selective activity-based probes
targeting KLK13, to our knowledge the first tool to analyze the presence of the active enzyme in
biological samples.
Keywords: KLK13; substrate specificity; combinatorial chemistry; fluorogenic substrate;
activity-based probe
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1. Introduction
Human kallikreins (KLKs) include 15 serine proteases with trypsin- or chymotrypsin-like
specificities [1]. KLKs are characterized by diverse tissue distributions and developmental stage
expression and, as such, have diverse biological functions [2]. Deregulated expression of KLKs
is characteristic for pathological conditions and is implicated in hypertension, inflammation,
neurodegenerative disorders and cancer [3–6]. Accumulating evidence associates KLKs with different
malignancies which points to their potential as biomarkers. KLK3, better known as prostate-specific
antigen (PSA), is widely used in detecting and monitoring prostate cancer progression [7,8], but other
kallikreins will likely prove useful to monitor a variety of cancers.
In homeostasis, human kallikrein 13 (KLK13) is primarily expressed in the testis, prostate, breast,
salivary glands, esophagus and the cervix [9–12] and is associated with certain skin pathologies,
including psoriasis vulgaris and atopic dermatitis [13]. Moreover, KLK13 is expressed at high levels
in some types of salivary gland tumors [14]. Furthermore, it has been reported as an independent,
favorable prognostic marker in breast [15] and ovarian cancers [16] and has potential clinical utility
as a prediction marker of gastric cancer cells’ response to chemotherapy [17]. As such, deciphering
the biological pathways involving KLK13 is of particular interest, and suitable tools to detect, label,
monitor and quantify its proteolytic activity are in great demand.
Proteins can be detected with high sensitivity even in very complex physiological samples using
immunolabeling. However, such methods are only rarely able to detect the level of activity, which
may differ significantly from the amount of an enzyme itself. Monitoring the activity of individual
proteases in complex samples is difficult, though possible, with the application of specific probes
labeling an enzyme of interest, based on its substrate preference. KLK13 substrate specificity was
investigated by Borgoño and colleagues [18]. Using 7-amino-4-carbamoylcoumarin (AMC)-based
positional scanning combinatorial libraries of peptide substrates they profiled the P4-P1 (nomenclature
according to Schechter and Berger [19]) subsite specificity of KLK13. They observed that KLK13 prefers
arginine at the P1 and P3 positions, while aliphatic and aromatic sidechains are preferred at the P4 and
P2 positions (Table 1). Additional insight into the primed subsite specificity of KLK13 was provided by
Andrade and colleagues [20] who used a fluorescence-quenched peptide substrate corresponding to the
specificities of KLK1 and KLK6 (ABZ-KLRSSKQ-EDDnp) [21] to design P3-P2′ spanning sub-libraries
which they used to profile the specificity of KLK13. These experiments confirmed a high preference of
KLK13 for basic residues (Arg preferred over Lys) at P1, but no clear specificity for P3, P2, P1′ subsites
was established (Table 1) [20]. These latter data, however, are disputable due to the design of the
substrate (see Section 3). Together, prior studies provide a partial, although incomplete, overview of
KLK13 substrate preference, especially concerning profiling of the primed sites. More importantly,
however, they have not translated into specific tools to monitor protease activity, particularly in
complex tissue samples.
In the present work, we re-evaluate the prior specificity profiling results of KLK13 at non-primed
positions using substrates of a different design. We extend the profiling at primed sites with extensive
positional scanning and provide a sensitive and selective internally quenched substrate with the
sequential motif encompassing the most efficiently recognized residues at the P4-P3′ subsites. The
substrate is converted into an inhibitor and further into an activity-based probe, which allows detection
of KLK13 in complex biological samples.
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Table 1. Summary of P4-P3′ residues most preferred by kallikrein 13 (KLK13) as determined by this and
prior studies. All percentage values were calculated and compared from each publication separately.
Activity on the most preferred residue was considered as 100% and the following amino acids were
then adjusted accordingly to the highest value for each position. Only amino acids with a threshold
over 50% are listed, with the exception of the P3′ values where an 80% threshold was used due to low
selectivity at that position (*). n.d.—not determined.
This Work Borgoño et al. [18] Andrade et al. [20]
P4 V (100%), K (62%) V (100%), Y (58%) n.d.
P3 R (100%), A (58%) R (100%)
K (100%), I (96%) R (80%),
F (74%), V (56%), H (56%)
P2 F (100%) M (100%), L (80%), F (65%) R (100%), I (94%), K (59%)
P1 R (100%) R (100%) R (100%)
P1′ S (100%) n.d. H (100%), K (61%)
P2′ T (100%), A (79%), S (79%), V (54%) n.d. R (100%)
P3′ Q (100%), G (93), S (89%), W (84%), N (82%) * n.d. n.d.
2. Results
To devise optimal substrates and activity-based probes suitable for monitoring the activity
of KLK13 we thoroughly profiled the substrate specificity of the enzyme. First, we assessed the
specificity at the P4-P1 subsites using a methodology resembling that of Borgoño and colleagues [18],
however, using different reporter groups and a different deconvolution scheme. Such an approach and
comparative analysis allowed us to minimize the effect of substrate design on the profiling outcome.
We used a fluorescence-quenched library of the general structure of ABZ-X4-X3-X2-P1-ANB-NH2
to profile the P1 residue specificity. In this library, each of the 19 sub-libraries contained a defined
proteinogenic amino acid residue at P1 while X4-X2 positions contained equimolar mixtures of those
residues. The library was deconvoluted using KLK13 by monitoring the absorbance (410 nm) of
released ANB-NH2 to ensure specific hydrolysis at the P1-ANB ester bond (unlike fluorescence which
is released no matter which bond is hydrolyzed). Using such a library, arginine was selected as the
preferred residue at the P1 site for KLK13, followed by lysine, characterized by less than 30% activity
of the arginine containing sub-library. The other sub-libraries, containing different residues at P1, were
not hydrolyzed (Figure 1A).
Subsites other than P1 were profiled, starting from P4, to better explore the likely weaker
interactions at this position before P3 and P2 were deconvoluted. A library of a general structure
ABZ-P4-X3-X2-Arg-ANB-NH2 was prepared by the mix and split method [22] and deconvoluted with
KLK13 while monitoring ANB-NH2 release. Valine was significantly preferred at the P4 subsite, with
lysine and arginine also accepted, but with lower preference compared to Val (Figure 1B). Bulky
sidechains of tyrosine and phenylalanine were accepted, as well as threonine, isoleucine, leucine and
histidine. Sub-libraries containing other residues at P4 were not hydrolyzed at a detectable level.
Val was fixed at the P4 subsite and the ABZ-Val-P3-X2-Arg-ANB-NH2 library was synthetized and
deconvoluted by monitoring ANB-NH2 release. Arginine was the most preferred residue at P3, but the
protease selectivity at this subsite was relatively low since many tested residues were recognized and
the relevant sub-libraries were hydrolyzed with comparable efficiencies (Figure 1C). Only glutamic
acid, aspartic acid, asparagine, glycine and tryptophan were excluded at P3 while substrates containing
histidine at this subsite were hydrolyzed only with negligible efficiency. Position P3 was fixed with
arginine and the ABZ-Val-Arg-P2-Arg-ANB-NH2 library was deconvoluted. Phenylalanine was
preferred at the P2 position followed by tyrosine and arginine (Figure 1D). Lysine, leucine, methionine
and serine were also recognized with notable efficiency while histidine, alanine and asparagine
containing substrates were hydrolyzed poorly. Other tested residues were not tolerated at the P2
position. Overall, the non-primed subsite specificity profiling of KLK13 allowed identification of a
kinetically preferred substrate: ABZ-Val-Arg-Phe-Arg-ANB-NH2 (Substrate 1).
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Figure 1. Substrate specificity of KLK13. Non-primed specificity was determined by deconvolution 
of ABZ-X4-X3-X2-Arg-ANB-NH2 libraries. Each sub-library (X-axis) was treated with KLK13 in 50 mM 
Tris-Cl (pH 7.5) containing 1 mM EDTA and 0.5 μM heparin at 37 °C. Absorbance of released 5-amino-
2-nitrobenzoic acid (ANB) was determined at 410 nm. Panel order reflects the deconvolution of the 
library, with P1 resolved first (A), followed by P4-P2 analysis (B–D). Primed subsites’ specificity was 
determined by deconvolution of the ABZ-Val-Arg-Phe-Arg-X1′-X2′-X3′-Tyr(3-NO2)-NH2 libraries (E–
G). Each sub-library was treated with the enzyme in 50 mM Tris-Cl (pH 7.5) buffer containing 1 mM 
EDTA and 0.5 μM heparin at 37 °C. The fluorescence of released ABZ-peptide (excited at 320 nm) was 
monitored at 450 nm. 
Figure 1. Substrate specificity of KLK13. Non-primed specificity was determined by deconvolution
of ABZ-X4-X3-X2-Arg-ANB-NH2 libraries. Each sub-library (X-axis) was treated with KLK13 in
50 mM Tris-Cl (pH 7.5) containing 1 mM EDTA and 0.5 µM heparin at 37 ◦C. Absorbance of released
5-amino-2-nitrobenzoic acid (ANB) was determined at 410 nm. Panel order reflects the deconvolution
of the library, with P1 resolved first (A), followed by P4-P2 analysis (B–D). Primed subsites’ specificity
was determined by deconvolution of the ABZ-Val-Arg-Phe-Arg-X1′-X2′-X3′-Tyr(3-NO2)-NH2 libraries
(E–G). Each sub-library was treated with the enzyme in 50 mM Tris-Cl (pH 7.5) buffer containing 1 mM
EDTA and 0.5 µM heparin at 37 ◦C. The fluorescence of released ABZ-peptide (excited at 320 nm) was
monitored at 450 nm.
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For profiling of primed subsites of KLK13, the peptidyl part of the favorable non-primed substrate
was incorporated into fluorescence-quenched substrate libraries of the following general formula:
ABZ-Val-Arg-Phe-Arg-X1′-X2′-X3′-Tyr(3-NO2)-NH2 where Tyr(3-NO2)-NH2 quenches the fluorescence
of ABZ. The P1′ library was evaluated first, by monitoring the fluorescence increase at 450 nm in the
presence of the protease. Serine was selected at P1′ over all other tested residues, but the specificity
of the protease at the evaluated subsite was relatively relaxed since many other residues were also
accepted, albeit with lower efficiency compared to serine (Figure 1E). Serine was fixed at the P1′ position
and the P2′ library was deconvoluted with KLK13. Small sidechains containing amino acids including
threonine, serine, alanine and valine were preferred at the P2′ subsite in comparison to other residues
(Figure 1F). Glutamic acid, aspartic acid and glutamine containing substrates were almost resistant to
proteolysis. Bulky, aromatic sidechains were also disfavored. Threonine was fixed at the P2′ position
and P3′ preference was evaluated. KLK13 exhibited almost no preference at this subsite (Figure 1G).
Only isoleucine, valine, leucine and phenylalanine were disfavored. Glutamine was fixed at the P3′
position to yield a kinetically preferred substrate ABZ-Val-Arg-Phe-Arg-Ser-Thr-Gln-Tyr(3-NO2)-NH2
(Substrate 2). These observations were validated, by re-synthesis of the optimized substrates, differing
only at the P3′ position (Gln, Glu, Gly, Ser, respectively). Kinetic parameters of the hydrolysis were
determined and confirmed limited selectivity of KLK13 at P3′ position. Although the P3′-Gln substrate
was preferred, others were recognized comparably, with a notable difference for the charged Glu
residue, which was hydrolyzed with approximately 3-fold lower efficiency (Table 2).
Table 2. Kinetic parameters of the selected KLK13-specific substrates. MWexp represent the MS-TOF
measured average mass of the compounds.
Substrate MWexp KM (µM) kcat (s−1)
kcat/KM
([M−1·s−1])
ABZ-VRFRSTQ-Tyr(3-NO2)-NH2 (2) 1247.0 10.0 ± 1.9 96.43 ± 7.15 (9.64 ± 1.08) ×106
ABZ-VRFRSTE-Tyr(3-NO2)-NH2 1249.1 24.7 ± 5.8 91.11 ± 11.61 (3.69 ± 0.40) ×106
ABZ-VRFRSTG-Tyr(3-NO2)-NH2 1175.9 19.7 ± 3.0 169.40 ± 12.40 (8.62 ± 0.37) ×106
ABZ-VRFRSTS-Tyr(3-NO2)-NH2 1220.7 14.7 ± 2.2 113.12 ± 6.87 (7.71 ± 0.67) ×106
ABZ-VRFR-ANB-NH2 (1) 858.8 17.8 ± 2.8 94.36 ± 3.05 (5.31 ± 0.34) ×106
While deconvolution of non-primed libraries is unambiguous in terms of the cleavage site (only
hydrolysis of P1-ANB-NH2 ester bond, but not other peptide bonds within the substrate results in
absorbance increase), the results of primed sites’ deconvolution may be complicated by secondary
cleavages (fluorescence is released no matter which peptide bond within the substrate is hydrolyzed).
First, the ambiguity may result from the fact that two arginine residues are present within the substrate
(note the primary specificity of KLK13 for arginine), and second, the selection of primed subsites may
result in a shift of the major cleavage site. To verify if either of the above was the case, the scissile peptide
bond was identified in each successive step of primed library deconvolution. To this end, the reaction
products were analyzed with fluorescence detected RP-HPLC coupled to MS. In each case only a single
and identical fluorescent peptide was identified, corresponding to ABZ-Val-Arg-Phe-Arg-OH (detected
MWexp = 695.8 Da) which signified that during deconvolution each Xn subsite truly corresponded to
the Pn′ subsite (Supplementary Figure S1; any shifted cleavages would result in additional peaks in
the HPLC chromatogram). In particular, ABZ-Val-Arg-Phe-Arg-Ser-Thr-Gln-Tyr(3-NO2)-NH2 was
exclusively hydrolyzed at the Arg-Ser peptide bond. No detectable hydrolysis at the Arg-Phe peptide
bond signifies the importance of subsites other than P1 in the determination of KLK13 specificity.
To determine the sensitivity of identified substrates in detecting KLK13 activity, decreasing
amounts of the enzyme were reacted with a constant amount of the substrate, and substrate hydrolysis
was recorded. Detectable fluorescence increase was still observed with substrate 1 at 1.56 nM
concentration of KLK13. Substrate 2 provided even more sensitive detection. Fluorescence increase was
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still detectable at 48.8 pM enzyme concentration (Supplementary Figure S2A,B). We also determined
the specificity constants which were over 5 × 106 M−1·s−1 for substrate 1 and nearly 10 × 106 M−1·s−1
for substrate 2 (Table 2).
Having identified a sensitive substrate for KLK13, we re-evaluated the pH optimum of the
protease activity. The proteolytic activity against substrate 1 was tested using a range of buffers with
overlapping pH in the range of 3 to 10. pH 9 was identified as optimal for processing of substrate
2 by KLK13 (Supplementary Figure S2C). However, the activity dropped sharply above this value
suggesting deprotonation of the catalytic histidine, while the low pH limit of activity was determined
by pH 6, likely reflecting the protonation of the Asp residue in the catalytic triad.
We next asked what the specificity of the most sensitive substrate 2 was in terms of recognition by
proteases other than KLK13. To this end, we tested hydrolysis of substrate 2 by a number of kallikreins
and cathepsins. KLK13 exhibited the highest activity towards the substrate; however, substrate 2
was also cleaved by a number of other kallikreins although with significantly lower efficiency, not
exceeding 20% of the activity of KLK13 (Figure 2). None of tested cathepsins hydrolyzed substrate 2.
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both these purposes. The KLK13 substrate devised in this study, (1), was converted to an inhibitor by 
inclusion of a chloromethylketone (CMK) warhead, and further into an activity-based probe (ABP) 
by attachment of a biotin tag linked on a varied length spacer (Figure 3A–C). As expected, all 
compounds inhibited KLK13 (Figure 3D), although the biotin extension slightly negatively affected 
the kinetics of inhibition (Figure 3D). In addition, the phosphonate warhead was evaluated, however, 
such inhibitors were poorly active and thus were discontinued early in the study. 
To determine the detection limit and to establish the optimal concentration of the probe we 
analyzed the concentration-dependency of ABP labeling. Increasing concentrations of the probe were 
incubated with 250 ng of KLK13 and ABP binding was analyzed by Western blot. Clear labeling was 
detected using 1 μM concentration and increased in intensity up to 1 mM. Nonetheless, only 1 μM 
concentration allowed specific detection of the active protease while higher probe concentrations co-
labeled the residual proKLK13 present in the sample (Figure 3E). Therefore, 1 μM ABP was used in 
all the following assays. To determine the detection limit in terms of protease concentration, the probe 
was incubated with decreasing concentrations of KLK13. Western blot analysis demonstrated that as 
little as 15 ng of KLK13 was detectable in the test conditions (Figure 3F). 
Figure 2. Selectivity of the optimized substrate 2 (ABZ-Val-Arg-Phe-Arg-Ser-Thr-Gln-Tyr(3-NO2)-NH2).
Activity of selected kallikrein family proteases (KLK1, KLK2, KLK3, KLK4, KLK6, KLK8, KLK12,
KLK13) and cathepsins (CatX, CatL, CatS, CatD, CatH, CatB) against the tested substrate was monitored
at equal enzyme concentrations in the KLK13-optimized buffer. The fluorescence of the released
ABZ-Val-Arg-Phe-Arg fragment was monitored at excitation and emission wavelengths 320 and 450
nm, respectively.
Sensitive substrates allow detection of protease activity in liquid samples, but it is often
advantageous to visualize the activity on solid supports (e.g., Western blot) or with high spatial
resolution (e.g., microscopy). Substrate-like activity-based probes have been demonstrated to serve
both these purposes. The KLK13 substrate devised in this study, (1), was converted to an inhibitor by
inclusion of a chloromethylketone (CMK) warhead, and further into an activity-based probe (ABP) by
attachment of a biotin tag linked on a varied length spacer (Figure 3A–C). As expected, all compounds
inhibited KLK13 (Figure 3D), although the biotin extension slightly negatively affected the kinetics of
inhibition (Figure 3D). In addition, the phosphonate warhead was evaluated, however, such inhibitors
were poorly active and thus were discontinued early in the study.
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curves method and are shown as mean ± SD from three replicates. The IC50 values were determined 
by linear regression to the initial fragment of the KLK13 activity vs concentration of the given inhibitor 
curve; (E) Biotin-conjugated ABPs specific for KLK13 were tested for protease detection in Western 
blot analysis. 250 ng of KLK13 was incubated with ABPs at indicated concentrations in TNET buffer 
for 1 h at 37 °C. ABP with a polyethylene glycol (PEG) linker showed higher sensitivity in comparison 
to the shorter version of the probe, allowing for KLK13 detection at 1 μM concentration and better 
discrimination between pro- and active KLK13 (observed as the higher molecular weight band); (F) 
Detection limit of KLK13 at an optimized probe concentration. Twofold serial dilutions of KLK13 in 
the range of 500 to 4 ng were incubated with 1 μM Bt-PEG-VRFR-CMK ABP in TNET buffer for 1 h 
at 37 °C. Labeling was detected by Western blot. The detection limit is estimated at 15 ng of purified 
KLK13.  
The applicability of ABPs for detection of KLK13 in biological samples was initially tested using 
culture supernatants of Leishmania tarentolae expressing the recombinant protease. Conditioned 
media from strains transfected with the empty plasmid and the non-transfected parent strain were 
used as controls. A clear band corresponding to KLK13 was detected by Western blot only in the 
expressing strain, but not in the control supernatants, confirming the specific labeling of KLK13 
(Figure 4A). A supernatant from the KLK13-non-expressing strain displayed a clear band exclusively 
in the KLK13-spiked sample, again demonstrating specific labeling. 
Figure 3. Structure and activity of the KLK13 activity-based probes. (A–C) Chemical structures of the
optimized compounds developed for KLK13; (D) Inhibitory activity of activity-based probes against
KLK13. Residual activity of KLK13 was determined in triplicates using Abz-VRFR-ANB-NH2 after
preincubation with tested ABPs. Kinetic parameters (kass (M−1·s−1)) were determined by the progress
curves method and are shown as mean ± SD from three replicates. The IC50 values were determined
by linear regression to the initial fragment of the KLK13 activity vs concentration of the given inhibitor
curve; (E) Biotin-conjugated ABPs specific for KLK13 were tested for protease detection in Western blot
analysis. 250 ng of KLK13 was incubated with ABPs at indicated concentrations in TNET buffer for
1 h at 37 ◦C. ABP with a polyethylene glycol (PEG) linker showed higher sensitivity in comparison
to the shorter version of the probe, allowing for KLK13 detection at 1 µM concentration and better
discrimination between pro- and active KLK13 (observed as the higher molecular weight band); (F)
Detection limit of KLK13 at an optimized probe concentration. Twofold serial dilutions of KLK13 in the
range of 500 to 4 ng were incubated with 1 µM Bt-PEG-VRFR-CMK ABP in TNET buffer for 1 h at 37
◦C. Labeling was detecte by Western blot. The detection limit is estimated at 15 ng of purified KLK13.
To determine the detection limit and to establish the optimal concentration of the probe we
analyzed the concentration-dependency of ABP labeling. Increasing concentr tions of the probe were
incubated with 250 g of K K13 d ABP binding wa analyzed by Western bl t. Clear label ng was
detected using 1 µM co centration and increased in intensity up to 1 mM. Noneth less, o ly 1 µM
conc ntrati allowed specific detection of the active protease while high r p obe concentrations
co-labeled the residual proKLK13 present in the sample (Figure 3E). Therefore, 1 µM ABP was used in
all the following assays. To determine the detection limit in terms of protease concentration, the probe
was incubated with decreasing concentrations of KLK13. Western blot analysis demonstrated that as
little as 15 ng of KLK13 was detectable in the test conditions (Figure 3F).
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The applicability of ABPs for detection of KLK13 in biological samples was initially tested
using culture supernatants of Leishmania tarentolae expressing the recombinant protease. Conditioned
media from strains transfected with the empty plasmid and the non-transfected parent strain were
used as controls. A clear band corresponding to KLK13 was detected by Western blot only in the
expressing strain, but not in the control supernatants, confirming the specific labeling of KLK13
(Figure 4A). A supernatant from the KLK13-non-expressing strain displayed a clear band exclusively
in the KLK13-spiked sample, again demonstrating specific labeling.
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specific KLK13 probe. Signal corresponding to the KLK13 molecular weight was detected in the 
KLK13-spiked samples in the presence of ABP. In addition, a lower-molecular weight band of 
unknown origin was detected in probe treated cell lysate. 
Figure 4. Bt-PEG-VRFR-CMK detection of KLK13 in biological samples. Effectiveness of the KLK13
probe was tested in the background of different media and cell lysates using Western blot. (A)
Conditioned culture media (CM) of Leishmania Expression System (LEXSY) strains stably transfected
with either empty pLEX or pLEXpKLK13 plasmids were preincubated with or w/o 1 µM KLK13 probe
for 1 h at 37 ◦C. KLK13 was detected in the presence of ABP only in the media from cells transfected
with pKLK13 and in the media of empty pLEX culture spiked with 250 ng KLK13; (B) Saliva was freshly
collected from healthy volunteers. Diluted samples were either vehicle-treated or spiked with 250 ng
of KLK13 and incubated with or without addition of 1 µM specific KLK13 probe. Signal corresponding
to KLK13 was detected exclusively in the KLK13-spiked sample in the presence of ABP; (C) 30 µg
of PMNs RIPA buffer cell lysate and 5 µg of TIGK cell lysate were either vehicle-treated or spiked
with 250 ng of KLK13 and were incubated with or without the addition of 1µM specific KLK13 probe.
Signal corresponding to the KLK13 molecular weight was detected in the KLK13-spiked samples in the
presence of ABP. In addition, a lower-molecular weight band of unknown origin was detected in probe
treated cell lysate.
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To further test the ability of the ABP to detect KLK13 in even more complex biological
fluids, we analyzed saliva and cell lysates of human blood neutrophils (PMN) and TIGK (gingival
keratinocyte-derived, immortalized cell line). Relatively low background was present, mainly an
unspecific signal found even in non-labeled samples likely signifying naturally biotinylated proteins.
No KLK13 was detected in the saliva or TIGK samples, thus demonstrating that either the enzyme
concentrations were below the detection limit or that KLK13 was absent in those samples. A similar
pattern was true for PMN lysates, a weak intensity lower-molecular weight band was detected in
labeled samples, although its origin is unknown. The KLK13 specific signal was clearly detected only
in KLK13 spiked samples. Overall, this demonstrates that the probes elaborated in this study are
suitable for detecting KLK13 activity even in complex biological fluids (Figure 4B,C).
3. Discussion
The kallikrein activome has been the subject of extensive investigation recently because monitoring
KLK involvement in signaling, cancer progression and metastasis is of great importance for biomarker
development and cancer pathophysiology. Therefore, development of kallikrein-directed methods
and approaches is urgently needed. Here we have described a combinatorial library approach to
evaluate the substrate specificity of KLK13, an enzyme involved in epithelial regulation. Unlike
previous studies, our approach allowed an unbiased determination of non-primed (P4-P1) and primed
(P1′-P3′) subsite specificity of the protease. In addition, we described the development of selective
activity-based probes targeting KLK13 which, to our knowledge, is the first such attempt to analyze
the presence of the active enzyme in biological samples.
Less comprehensive approaches to profiling KLK13 specificity were previously undertaken [18,20]
and our results are in general agreement with these, while significantly extending the prior data. The
most important determinant of KLK13 substrate specificity was located at the P1 position, exactly
as expected for an S1 family protease. The preference for arginine at this subsite was clear, while
lysine was recognized at the P1 position with significantly lower efficiency. Further analysis revealed
a weaker selectivity at the P4-P2 positions. P4 favored Val and to a lesser extent Lys and Arg. This
corresponds to the previous results of Borgoño et al., where Val was also the most preferred amino acid
at that position. Nonetheless, our analysis of the P4 preference indicated Lys and Arg as the second and
third most preferred residues, in contrast to Tyr as found in the work of Borgoño and colleagues. We
also saw recognition of tyrosine at this subsite, but with low preference. This difference likely indicates
the influence of the deconvolution scheme and substrate design on profiling results, especially where
secondary, less pronounced specificities are concerned.
KLK13 specificity analysis at the P3 position revealed low selectivity. Arg was the most-preferred
residue, but substrates containing multiple other residues were also efficiently hydrolyzed. Remarkably,
Gly, Glu, Trp, Asp and Asn were incompatible with the P3 subsite—an observation unexpected at a
subsite with otherwise poor selectivity. Such a result is again in partial agreement with previous reports.
Borgoño et al. also identified Arg as the most preferred aminoacid at P3. Yet in their study, no other
residues, with the exception of Lys, His, Val and Phe, were accepted at the P3 subsite. Andrade et al.
also found Arg was one the most preferred residues at P3 subsite; however, in this instance, together
with Lys Ile, Phe and to a lesser extent His, Val, Ala, Gln, Asn and Leu. Therefore, the preference for
Arg at P3 is well established while secondary preference is less evident. Both we and Andrade et al.
observed relatively broad specificity at this subsite, in contrast to Borgoño et al.’s report.
Due to the characteristic structure of the S2 subsite in KLK13 we expected limited specificity
at the P2 position. Besides KLK1-3, KLK13 has the longest kallikrein loop among the KLK-family
proteases, due to a characteristic 5-aa insertion. This is significant since the kallikrein loop shapes the
S2 subsite. Indeed, our data support the prediction that a structurally restricted S2 subsite corresponds
to extended specificity at this position. We found that Phe was favored at the P2 position, followed
by Arg, Tyr and Leu. Other amino acids, including Lys, Met, Ser, His and Ala were recognized with
much lower efficiency, and all other residues were disfavored at P2. Previous reports partially differ in
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their description of P2 preference, both between each other and with respect to our data. Borgoño et al.
reported preferences for norleucine, Leu and for Phe, being the third most preferred residue, an
observation accompanied by surprisingly low selectivity of KLK13 towards P2 residues in their study.
In turn, Andrade et al. identified Arg and Ile as the most preferred residues at P2, followed by Lys,
Leu and Phe. Although a certain consensus is evident, with Phe and Leu being reported among the
most preferred residues in all three experimental setups, obvious differences are also noted. Our data
are in better agreement with Andrade et al., indicating Arg among the preferred residues, a finding in
contrast to Borgoño et al.’s report, where Arg was clearly disfavored. These differences are difficult to
explain with substrate design only and may suggest certain cooperativity of the binding sites.
Analysis of specificity of KLK13 at primed positions was attempted only by Andrade et al. [20],
although in a relatively less extensive setup. A series of peptides was synthesized, covering only 13
amino acid residues (out of 20 natural amino acids) in P1′ and P2′ positions, respectively. Our analysis
was based on a more unbiased approach, where full libraries covering 20 residues were constructed
for P1′, P2′ and P3′ positions. Moreover, the substrates used by Andrade et al. were based on an
a priori selected constant non-primed region, while ours used a sequence of the most kinetically
preferred substrate of KLK13. We found that KLK13 displayed a significant preference towards Ser in
P1′ position, however Ala, His, Arg, Lys, Asn and Gln were also accepted with 30% efficacy, compared
to the optimal sub-library containing Ser residue. This indicated limited selectivity of KLK13 in the P1′
position, in general agreement with previous reports, which identified Lys, His, Asn and Ser among the
preferred residues. Notable differences were observed in recognition of Phe, which was disfavored in
our study while being identified as one of the preferred amino acids in the abovementioned report. On
the other hand, we have identified Arg as a residue recognized with efficiency comparable to that of Lys
in P1′, which is in contrast to the previously described limited recognition of Arg at this position. Again,
such differences could be related to the different design of tested substrates at the P4-P1 subsites and
thus, different subsite cooperation. Andrade et al. determined P1′ specificity using the substrates of the
general design ABZ-KLR↓XSKQ-EDDnp, as opposed to ABZ-VRFR↓P1′X2X3-Tyr(3-NO2)-NH2 used in
this study. The presence of additional P4 Val, optimal P3 Arg and, most importantly, a large P2 Phe
residue in our substrate libraries could affect the cooperativity of subsites and result in the observed
varied selectivity of the enzyme with different substrate design. Indeed, KLK-family members are
characterized by similar structure and organization of the substrate binding cleft [23,24], yet differ
significantly in specificity, a phenomenon partially explained by the apparent cooperativity of the
substrate binding subsites (where small differences at particular subsites may result in significant
differences in the overall preference). For example, prior analysis of KLK14 specificity indicated strong
interaction between S3 and S4 binding pockets, allowing identification of a preferred substrate, which
was hydrolyzed significantly better than substrates previously identified using PC-SCL and phage
display [25].
Analysis of the P2′ position revealed moderate selectivity, with Thr, Ser, Ala and Val being the
most frequently selected amino acids, with most other residues still recognized, and only Asp, Glu
and Gln being clearly rejected. These findings confirm the results of prior studies indicating moderate
selectivity of KLK13 in the P2′ position except for Asp-containing substrates which were completely
excluded. The notable differences concerned only Arg, Leu, Phe and Gln being the most preferred
residues reported in the Andrade et al. study. We again attribute this difference to substrate and
deconvolution scheme design which has a significant effect especially at subsites with lower selectivity.
To our knowledge this report was the first to analyze P3′ specificity of KLK13. KLK13 did not show
a stringent specificity at this position, with the majority of residues accepted with similar efficiency.
The exceptions were certain hydrophobic residues which were clearly disfavored: Val, Leu, Ile, Phe.
Based on comparative structural analysis, interactions between KLK13 and the substrate at
positions further than P4 and P3′ are not expected and therefore our study provides a full overview
of KLK13 substrate specificity. Our specificity profiling is in general agreement with prior studies,
though expands the previous findings in a consistent design over all the subsites. Certain differences
Int. J. Mol. Sci. 2019, 20, 1557 11 of 18
in profiling results were observed, which are especially evident when secondary specificities are
considered. The variation in results may be explained by significant differences in the experimental
design. First, our KLK13 was produced in a eukaryotic expression system which provided mammal-like
glycosylation within the core glycan. Borgoño et al. obtained the enzyme in Pichia pastoris, an approach
which results in excessive, unnatural glycosylation, reaching a 1:1 ratio of glycan and protein. Andrade
and colleagues used baculovirus-expressed KLK13, obtaining glycosylation similar to our enzyme
(note that our profiling data corresponds better to that of Andrade et al., indeed indirectly suggesting
the influence of glycosylation). In addition, the experimental conditions differed significantly between
the assays, as high-concentration (1–1.5 M) sodium citrate was used as an activator by some authors
(Andrade et al.). All the parameters—excessive glycosylation, presence of cosmotropic activators and
different substrate library design—may have affected the apparent activity and/or specificity of the
enzyme, particularly in the less specificity defined positions and especially the secondary specificities.
Therefore, not surprisingly, primary specificity in critical positions (P1, P2, P3) determined in our study
fully corroborates the findings of prior reports. In contrast, specificity at less defined P′ positions, and
secondary specificities show more variability. Nonetheless, we believe that because of its unbiased
nature our approach presents the optimal method for determination of the KLK13 specificity. This is
supported by obtaining an optimal substrate, characterized by the kcat/Km ≈ 107 M−1·s−1, the best
KLK13 substrate described to date.
Based on the determined optimal substrate structure, we designed a KLK13 inhibitor by
incorporating chloromethylketone (CMK) as a warhead. The CMK-inhibitor was further used to
design two variants of biotin-tagged activity-based probes, one with the label attached directly at
the N-terminus and the second with the PEG linker between the peptide fragment and the label.
All three inhibitors demonstrated similar efficiency, with IC50 in the low-micromolar range and kass
in the range of ~0.5–2.5 × 102 M−1·s−1, however the presence of biotin in close proximity to the
peptide part (without the PEG linker) slightly decreased the efficiency of inhibition. We determined the
optimal concentration of the probe (low micromolar range) suitable for specific labeling of the active
form of KLK13 only (as opposed to pro-KLK13). We also estimated the detection limit of the ABP at
around 15 ng of the purified KLK13. These values are indeed satisfactory since similar concentrations
of papain-like proteinase-specific activity-based probes—DCG-04 and its derivatives—were used
in numerous reports [26–29]. Similarly, the detection limit established here, although significantly
higher compared to the optimized antibody-based techniques [30], is comparable to that reported for
activity-based probes targeting other enzyme families [31]. Therefore, the KLK13-specific activity-based
probe designed here, Bt-PEG-VPR-CMK, is suitable for application in research aimed at the elucidation
of KLK13 biological functions. Nonetheless, further development of the probe is still desired. In
applications involving biotin, the sensitivity of the assay is limited by the background signal due to
ubiquitous presence of endogenously biotinylated proteins in biological samples. Further optimization
of the probe, e.g., by incorporation of a radioactive isotope label, would likely increase the sensitivity. In
parallel, development of ABPs specific to different kallikreins and labeled with fluorophores of different
spectral properties, would allow simultaneous detection of KLK-derived activities in complex samples.
Our probes efficiently detected KLK13 activity in complex biological samples, with low
background in the analyzed cell lysates, culture medium and saliva. Notably, a weak staining of a
lower molecular weight product in PMN-derived lysates was observed. This may indicate non-specific
binding of the probe, yet it is worth noting that KLK13 expression was indeed detected in human
PMN cells [32] and observed mass differences may reflect the presence of different isoforms of KLK13,
which remains to be determined experimentally.
KLK13 was detected in all samples after spiking with the recombinant enzyme, confirming the
probe stability and reactivity in complex biological samples. Additionally, the presence of KLK13
was detected in non-concentrated culture medium of the KLK13-expressing LEXSY strain, indicating
good kinetics of the probe. These promising results open avenues for further research aimed at the
elucidation of KLK13 activity in tissues. Similar approaches with cathepsin-specific ABPs allowed for
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the detailed description of CatB, L and S trafficking and activation in cell-based models of thyroid
epithelium [33]. Most importantly, the availability of cathepsin-specific activity-based probes allowed
for the analysis of their activity in the tumor environment in vivo [34], an exciting perspective, given
the long-postulated role of kallikreins in the tumor progression, development and metastasis [35,
36]. Herein, we have presented the first tool allowing for similar analysis of the kallikrein-related
peptidase 13.
In conclusion, this report provides a first unbiased analysis of KLK13 protease specificity
using optimized substrate libraries spanning both non-primed and primed subsites. We
developed a highly-sensitive substrate (ABZ-Val-Arg-Phe-Arg-Ser-Thr-Gln-Tyr(3-NO2)-NH2) suitable
for determination of KLK13 activity, characterized by kcat/Km ≈ 107 M−1·s−1. Even more importantly
we delivered a validated, KLK13-optimized activity-based probe with the biotin tag. Both materials
provided are valuable tools in protease research. The probes are active and suitable for detection of
KLK13 in complex biological samples, hence opening new possibilities for further research on the
biological role of KLK13 protease.
4. Materials and Methods
4.1. Expression and Purification of Recombinant Human KLK13
Total RNA was isolated from human airway epithelial (HAE) cells, cDNA was synthesized
with the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Warsaw,
Poland) and used as a template for proKLK13 gene amplification. To modify the product
in a way suitable for cloning, a 3-step PCR was performed with primers (Forward1:
5′-GACGACGACAAGCTTGGTGACGTTGCCAATGCTGTG-3′, Forward2: 5′-CCATCATCAC
CACGAC GACGAC GACAAGC TTGGTGACGTTG-3′, Forward3: 5′-ATATCTAGA CATCACCATC
ATCACCACGACGACGAC-3′ and Reverse 5′-ATAGCGGCCGCTTATTGTGGGCCCT TCAACCAT-3′)
where the product of the first amplification was used as the template for the following PCR reaction
and the same reverse primer was used for all of the reactions. The final product was cloned into
the pLEXSY_I-blecherry3 plasmid (Jena Bioscience, Jena, Germany) with restriction sites NotI and
XbaI. Correct insertion of the gene of interest into an open reading frame and the presence of a signal
peptide was confirmed by sequencing. Plasmid pLEX-proKLK13 was amplified in Escherichia coli DH5α
(Thermo Fisher Scientific) with ampicillin selection followed by Midiprep (A&A Biotechnology, Gdynia,
Poland) clean up and linearized with SalI (Thermo Fisher Scientific). All preparations for transfection,
selection and expression in the host L. tarentolae strain T7-TR were performed according to the Jena
Bioscience protocol for inducible expression of recombinant proteins secreted to the medium (Jena
Bioscience). In brief, the host cells were electroporated with linear DNA construct and stable clones
were selected with an appropriate antibiotic. Expression of proKLK13 was induced with 15 µg/mL
of tetracycline (BioShop, Burlington, Canada) over 3 days, protein was precipitated out of the media
with 80% ammonium sulfate, and the precipitates were collected by centrifugation at 15,000 RCF for
30 min at 4 ◦C, suspended in 10 mM sodium phosphate pH 7.5 and dialyzed overnight at 4 ◦C against
the same buffer. The protein was recovered on immobilized nickel ions (GE Healthcare, Warsaw,
Poland) in the presence of 10 mM benzamidine and purified according to the resin manufacturer’s
protocol. Obtained fractions were analyzed by SDS-PAGE in reducing conditions, fractions containing
proKLK13 were concentrated with Vivaspin 2 (Sartorius, Göttingen, Germany) and the protein was
further purified on Superdex S75 pg (GE Healthcare) in 20 mM Tris-HCl, 0.5 M NaCl, pH 7.5. Fractions
containing proKLK13 were concentrated with buffer exchange to 50 mM, Tris-HCl, 150 mM NaCl,
pH 7.5. After purification and self-activation at 37 ◦C for 24 h, KLK13 was active-site titrated with
recombinant LEKTI/SPINK6 as described by Kantyka et al. (2011) [37].
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4.2. Individual Peptide and Peptide Library Synthesis
Individual substrates were synthesized manually on TentaGel S RAM resin (substitution level of
0.25 meq/g; RAPP Polymere, Tübingen, Germany) as the solid support. The Fmoc/tBu procedure was
used. Coupling was carried out using an equimolar mixture of protected amino acid residue, DIPCI
(N,N′-diisopropylcarbodiimide) and HOBt (1-hydroxybenzotriazole).
Peptide libraries were synthesized by the mixing-portioning method [22]. Specifically, 17.7 g
of the solid support (TentaGel S RAM resin, RAPP Polymere, Tübingen, Germany) was used
to synthesize the non-prime, ANB-based library. After the removal of Fmoc protecting groups
with 20% piperidine in DMF/NMP (1:1, v/v), the resin-bound amine group was acylated with
5-amino-2-nitrobenzoic acid (ANB) using the N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uranium
tetrafluoroborate (TBTU)/4-dimethylaminopyridine (DMAP). Briefly, two equivalents of ANB and
two equivalents of TBTU/DMAP were dissolved in DMF and added to the resin. After 30 s, four
equivalents of N,N-diisopropylethylamine (DIPEA) were added. The whole mixture was stirred
for 3 h. The solution was filtered, and the resin was washed extensively with DMF. To achieve a
complete resin substitution the procedure was repeated three times. Then, the first Fmoc-protected
amino acid was conjugated to ANB using a POCl3/pyridine system [38]. After deprotection all
subsequent Fmoc-protected amino acids were conjugated using the DIPCI/HOBt coupling system. A
threefold excess of the reagents was applied, relative to the active resin sites. Finally, the Boc protected
2-aminobenzoic acid was introduced as the N-terminal group. The library of internally quenched
ABZ/Tyr(3-NO2) peptides was synthesized as described above using 15.1 g TentaGel S RAM resin and
starting with Fmoc-protected 3-nitro-L-tyrosine.
Following synthesis, the peptides were cleaved from the resin using a trifluoroacetic acid
(TFA)/phenol/triisopropylsilane/H2O mixture (88:5:2:5, v/v) [39]. The purity of the peptides was
evaluated on a RP-HPLC Jasco LC System (Jasco, Tokyo, Japan) equipped with Supelco Wide Pore C8
column (8 × 250 mm) and ultraviolet-visible (UV-VIS, 226 nm) and fluorescent detectors (excitation
320 nm, emission 450 nm). A linear gradient from 10% to 90% B within 40 min was applied (A: 0.1%
TFA in water; B: 80% acetonitrile in A). Mass spectra were recorded using a Biflex III MALDI TOF
mass spectrometer (Bruker, Karlsruhe, Germany) on α-cyano-4-hydroxycynnamic acid (CCA) or
2,5-dihydroxybenzoic acid (DHB).
4.3. Activity-Based Probe Synthesis
The activity-based probes were synthesized in a two-step procedure. First, the peptide
fragments (Ac-Val-Arg-Phe-OH, Bt-Val-Arg-Phe-OH and Bt-PEG-Val-Arg-Phe-OH) were obtained
manually on a 2-chlorotrityl resin as the solid support. Peptides were cleaved from the resin
with side-chain protecting groups [40]. One molar equivalent of each peptide was dissolved in
DMF and 1.1 molar equivalent of L-arginine chloromethylketone, 2 molar equivalents of DEPBT
(3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one) and 3 molar equivalents of DIPEA were
added. The reaction mixture was stirred for 6 h. The organic solvent was evaporated. The side-chain
protecting groups were removed using trifluoroacetic acid (TFA)/phenol/triisopropylsilane/H2O
mixture (88:5:2:5, v/v) [39].
4.4. Library Deconvolution
The specificity of KLK13 at nonprime subsites was evaluated using an ABZ/ANB library and the
enzyme in concentrations ranging from 8.32 × 10−8 to 1.75 × 10−8 M. Deconvolution of the primed
subsite library was carried out using KLK13 at concentrations from 1.25 × 10−8 to 1.25 × 10−9 M.
Deconvolution was performed using the iterative method in solution [41]. Freeze-dried samples of
each sub-library were dissolved in dimethyl sulfoxide (DMSO) to the final concentration of 5 mg/mL.
20 mL of each tested sub-library was supplemented with an assay buffer (180 µL; 50 mM Tris-Cl
(pH 7.5) containing 1 mM EDTA and 0.5 µM heparin [20] and with the enzyme. All measurements
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were performed using the Omega plate reader (BMG Labtech, Ortenberg, Germany). Hydrolysis was
monitored for 30 min at 37 ◦C by the ANB absorbance at 410 nm (for the non-primed library) or at
ABZ excitation wavelength of 320 nm and emission at 450 nm (for the primed library).
The site of hydrolysis was determined after each step of deconvolution of primed site library and
for both final substrates (1 and 2) by RP-HPLC monitored by fluorescence detection and MS.
4.5. Determination of Kinetic Parameters
Kinetic parameters (Michaelis constants (KM) and catalytic constants (kcat)) were determined
at a KLK13 concentration of 1.25 × 10−9 M. All measurements were performed in triplicate and the
systematic error, expressed as a standard deviation, did not exceed 20%. The specificity constant
(kcat/KM) was calculated from kcat and KM. The details of kinetic studies and the method of calculating
kinetic parameters have been described previously [42].
4.6. Determination of Detection Limit
The detection limit was established by analyzing the correlation between an increase
in absorbance/fluorescence and enzyme concentration at constant quantities of each,
ABZ-Val-Arg-Phe-Arg-ANB-NH2 (Substrate 1) and ABZ-Val-Arg-Phe-Arg-Ser-Thr-Gln-Tyr(3-NO2)-NH2
(Substrate 2).
4.7. pH Dependence of KLK13 Activity
The pH dependence of KLK13 (1.25 nM) was established at 37 ◦C using substrate 2 (6.15 µM) in
following buffers: citric acid/sodium citrate (pH 3), sodium acetate/acetic acid (pH 4 and 5), MES
(pH 6), MOPS (pH 7), HEPES (pH 8) and TRIS (pH 9 and 10).
4.8. Selectivity Assessment
Substrate 2 (6.15 µM) was incubated with tested kallikreins (KLK1, KLK2, KLK3, KLK4, KLK6,
KLK8, KLK12, KLK13) and cathepsins (CatX, CatL, CatS, CatD, CatH, CatB), all at a concentration
of 1.25 nM, at 37 ◦C in 50 mM Tris-Cl (pH 7.5) buffer containing 1 mM EDTA and 0.5 µM heparin.
Proteolytic activity was assayed as an increase in fluorescence at 450 nm.
4.9. Determination of Inhibitory Activity
The kinetic parameters of inhibition were determined using a progress curve model for
irreversible inhibition, as described previously [43,44]. Briefly, a series of concentrations
(0–50 µM) of activity-based probes (ABPs) obtained in this study (Ac-Val-Arg-Phe-Arg-CMK,
Bt-Val-Arg-Phe-Arg-CMK and Bt-PEG-Val-Arg-Phe-Arg-CMK) was mixed with a substrate
ABZ-Val-Arg-Phe-Arg-Ser-Thr-Gln-Tyr(3-NO2)-NH2, (Substrate 2, final concentration 10 µM). Upon
the addition of KLK13 (final concentration 10 nM), the fluorescence of the hydrolyzed substrate was
monitored in each sample at excitation and emission wavelengths of 320 and 450 nm, respectively,
for 1 h using a microplate reader Gemini EM (Molecular Devices, Berkshire, UK). The reactions were
carried out in 200 µL of final volume of 50 mM Tris-Cl (pH 7.5) containing 1 mM EDTA and 0.5 µM
heparin at 37 ◦C. Progress curves were fitted to the resulting data points and then kobs derived from
each curve was plotted against inhibitor concentration. Final values of kass were calculated by linear
regression and presented as mean ± SD of three independent replicates. IC50 values were determined
by incubating increasing amounts of each inhibitor with 10 nM KLK13 and linear regression to the
initial fragment of the resulting curve.
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4.10. Detection of KLK13 Using ABPs
Purified active KLK13 (250 ng) was preincubated with increasing concentrations of
Bt-PEG-VRFR-CMK or Bt-VRFR-CMK in TNET buffer (0.1 M Tris-HCl, 150 mM NaCl, 5 mM EDTA,
0.05% Tween-20, pH 7.5) for 1 h at 37 ◦C. Samples were analyzed by SDS-PAGE followed by wet
electrotransfer onto a PVDF membrane (GE Healthcare). Membranes were blocked in 5% BSA in
TBS buffer (50 mM Tris-HCl, 0.5 M NaCl, pH 7.5) with 0.1% Tween overnight, at 4 ◦C, followed by
incubation with 1:10,000 diluted Streptavidin-HRP (Sigma Aldrich, S2438, Poznan, Poland) for 2 h
at RT. After intensive washing with TBS buffer with 0.1% Tween, the signal was developed with
Pierce ECL WB substrate (Thermo Fisher Scientific) and visualized manually using AGFA films (Agfa
HealthCare, Mortsel, Belgium). To establish the detection limit, decreasing amounts of active KLK13
(ranging from 3.9-500 ng) were preincubated with 1 µM Bt-PEG-VRFR-CMK in TNET buffer for 1 h at
37 ◦C and visualized by streptavidin-HRP Western blot as described above.
4.11. Detection of KLK13 in Biological Samples
The activity of KLK13 was analyzed in 3-day conditioned LEXSY media using strains stably
transfected with empty pLEX and pLEXpKLK13 plasmids. Undiluted culture supernatant (27 µL) was
preincubated with or without 1 µM Bt-PEG-VRFR-CMK probe for 1 h at 37 ◦C, followed by Western
blot analysis.
Saliva, freshly collected from healthy donors, was clarified by centrifugation and diluted 2-fold
with sterile TNET buffer. The samples were spiked with 250 ng of KLK13 and incubated with 1 µM
tested activity-based probe for 1 h at 37 ◦C, followed by Western blot analysis (final concentration of
saliva in samples was 25%).
Cell lysates were prepared as follows: neutrophils were isolated from the blood of healthy
donors [45] and lysed in RIPA buffer (25 mM Tris pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS,
0.5% sodium deoxycholate)
Human telomerase immortalized keratinocytes (TIGK, ATCC® CRL-3397TM, LGC Standards,
Teddington, UK) were cultured in KBM-GoldTM (Lonza, Warsaw, Poland) keratinocyte basal medium
supplemented with Single QuotesTM (Lonza, Warsaw, Poland) at 37 ◦C and 5% CO2. Cells were
collected by trypsin digest and washed with PBS. Finally, cells were resuspended in TNET buffer,
lysed on ice with a hand sonicator (amplitude 60%, 20 cycles, 1 s pulse, 5 s break; UP50H Ultrasonic
Processor, Hielscher, Teltow, Germany) and cleared by centrifugation. Cell lysates (30 µg of PMN and
5 µg of TIGK lysate protein content, respectively) were spiked with 250 ng of recombinant KLK13 and
incubated with 1 µM specific ABP for 1 h 37 ◦C. All samples were analyzed with Western blot and
compared to the unspiked and unlabeled controls.
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Abbreviations
KLK Kallikrein-like proteinase
ABP Activity-based probe
PEG Polyethylene glycol
LEXSY Leishmania Expression System (LEXSY)
HAE Human airway epithelial
ANB 5-Amino-2-nitrobenzoic acid
TBTU N,N,N′,N′-Tetramethyl-O-(benzotriazol-1-yl)uranium tetrafluoroborate
DMAP 4-Dimethylaminopyridine
DIPEA N,N-Diisopropylethylamine
DIPCI N,N′-Diisopropylcarbodiimide
HOBt 1-Hydroxybenzotriazole
ABZ Albendazole
TFA Trifluoroacetic acid
CCA α-Cyano-4-hydroxycynnamic acid
DHB 2,5-Dihydroxybenzoic acid
DEPBT 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one
TIGK Telomerase immortalized keratinocytes
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